Engineering oncolytic measles virus to circumvent the intracellular innate immune response.
about
Systemic delivery of oncolytic viruses: hopes and hurdlesNew viruses for cancer therapy: meeting clinical needsEnhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responsesOvercoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint BlockadeFrom scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancerMeasles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy.Infection and killing of multiple myeloma by adenovirusesEnhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinomaViral oncolysis - can insights from measles be transferred to canine distemper virus?Impact of tumor microenvironment on oncolytic viral therapyOncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.Success of measles virotherapy in ATL depends on type I interferon secretion and responsiveness.Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.Gene therapy progress and prospects cancer: oncolytic viruses.Attenuated oncolytic measles virus strains as cancer therapeuticsDeficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain.The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor MicroenvironmentAttenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys.CD8(+) T-cell Immune Evasion Enables Oncolytic Virus ImmunotherapyVesicular stomatitis virus as a treatment for colorectal cancerChemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded.Oncolytic measles virus strains as novel anticancer agents.Measles virus for cancer therapy.Pharmacologic and chemical adjuvants in tumor virotherapy.The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.Differential cellular immune responses to wild-type and attenuated edmonston tag measles virus strains are primarily defined by the viral phosphoprotein gene.Use of attenuated paramyxoviruses for cancer therapy.Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses.Oncolytic virotherapyAntiglioma oncolytic virotherapy: unattainable goal or a success story in the making?Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most EffectiveClinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer.Advances in the design and development of oncolytic measles viruses.Measles virus causes immunogenic cell death in human melanoma.Oncolytic viruses from the perspective of the immune system.Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics.
P2860
Q21284969-430F3945-80FC-4538-8CD8-2454A9274A3AQ24567699-6DC53110-0A1F-4AA1-8CB1-D336F8039D59Q24631361-93B859B4-5B0A-43B0-9FF4-64F552265580Q26769977-B7253196-71B1-41C7-B811-142231191BFFQ26822694-257329FB-8E56-4DE6-B91F-DA4236A8048EQ30557338-D18CAFED-950E-4A45-8988-6CEF11063EEEQ33691833-6943E5BD-E9DA-493F-95FB-1036C329A41FQ33731148-3601B6A5-F6AB-491E-88D4-E4093E6A4FAAQ33820717-1FA9441C-5110-46A2-8F55-C6A622276BF4Q33895533-3D5BBED1-ACD5-466A-BF86-459D6FE4AF56Q33906116-8A0E85F6-FB31-489B-ADD4-D78E0C4FD0EBQ33930081-2696F0B2-7BD0-4621-AB7D-931B5F9EC2FAQ34053730-39C72F07-68D1-493B-A30C-2858B3029D48Q34421151-A5144DDA-2955-434E-9B92-888C13D40D88Q34770611-AEA5D0DD-C7A4-48D2-A428-E0358DBE5FBEQ35818876-E2BB0E21-3EDE-4026-8F5D-1A4F70942C1BQ36140704-850FBF91-C747-418F-ADD5-02D414672DA3Q36658280-023F1D3B-EF9D-449E-A39F-56D054A55EBEQ36673332-2E989D93-4981-41EF-A09F-EB8D752A00F0Q36753953-D85A8A9D-A732-441E-9744-2CF28538E399Q36928614-2CD148FE-0317-4816-B024-C3F6BC46EECEQ36937117-60BB7026-EEEF-405A-9CEC-8FEBFF07ED70Q37191007-ECB4A30C-6088-46A4-88B8-E7B806D5A203Q37261017-738CC237-D72E-4605-A3E7-FCC066DF76D5Q37388577-16D747BC-7597-4E06-8BF8-A5E266AE5F26Q37492540-CFB46892-4B05-4CD1-BFA1-FB8F7468FA87Q37561072-97C91C99-9634-4AC4-845B-8822CA55B3CFQ37564490-395A59B8-CDA6-4F5F-8D7F-DEE63F20CBF2Q37583896-18F68254-880D-440B-8DF9-455A2C112505Q37810599-56E97B8C-84DE-4DF8-A4DD-6C76EE444D63Q37933439-846C4B08-CF67-42DF-B580-B4107AE5CDEAQ38025263-46F11278-4691-4B68-A3A9-B171491E656AQ38218674-05B31519-1557-44C1-8A29-5C96B91DF6CFQ38685020-4532276F-AB2D-4BB2-A66C-E62FEBA991ADQ38754467-BCDAC948-1424-43C0-A0A7-96D7A098A2F9Q38808823-E9C20172-4195-4437-8D82-56E5218F5575Q38924566-13DEC35B-F92C-4706-9974-F94839FF1E76Q39428453-A532E4B6-FDDE-4578-8904-4B55BD6E03B7Q39974038-36A8A12A-CB36-4D5B-B431-F2CDE0602557Q40162604-6E6E4C31-73BD-48F5-BC10-AF1D7D17C2CC
P2860
Engineering oncolytic measles virus to circumvent the intracellular innate immune response.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Engineering oncolytic measles ...... llular innate immune response.
@en
Engineering oncolytic measles ...... llular innate immune response.
@nl
type
label
Engineering oncolytic measles ...... llular innate immune response.
@en
Engineering oncolytic measles ...... llular innate immune response.
@nl
prefLabel
Engineering oncolytic measles ...... llular innate immune response.
@en
Engineering oncolytic measles ...... llular innate immune response.
@nl
P2093
P2860
P50
P356
P1433
P1476
Engineering oncolytic measles ...... llular innate immune response.
@en
P2093
Ianko Iankov
Kosei Hasegawa
Mary Harvey
P2860
P304
P356
10.1038/SJ.MT.6300076
P577
2007-01-16T00:00:00Z